06 February 2024
06 February 2024
Blenrep combined with BorDex was found to significantly improve progression-free survival (PFS) compared with daratumumab combination.
The global, open-label, multi-centre study will analyse PRO1107's ability to treat various cancers.
J&J’s nipocalimab met primary endpoints in Phase III and II trials for myasthenia gravis and Sjogren’s disease, respectively.
ARCT-154 demonstrated a longer-lasting immune response than Comirnaty in the Phase III study.
Treatment with TDM-105795 resulted in hair growth in male androgenetic alopecia patients.
France-based Carthera’s SonoCloud implant temporarily allows enhanced chemotherapy drug delivery to brain tissue.
Yupelri was one of the first once-daily nebulised bronchodilators to gain US Food and Drug Administration (FDA) approval.
J&J MedTech’s Varipulse Platform demonstrated 12-month freedom from atrial arrhythmia recurrence in approximately 80% of the patients in inspIRE and admIRE trials.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
